{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:36:13Z","timestamp":1778124973277,"version":"3.51.4"},"reference-count":9,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Maribavir was approved by the US Food and Drug Administration for the treatment of patients aged \u226512\u2009years and weighing \u226535\u2009kg with posttransplant cytomegalovirus infection\/disease refractory (with\/without resistance) to valganciclovir, ganciclovir, cidofovir, or foscarnet, with an oral dose of 400\u2009mg twice daily. With no pediatric clinical data available and difficulty in trial recruitment, population pharmacokinetic modeling and simulations were conducted to predict the pharmacokinetics and inform maribavir dosing in adolescents.<\/jats:p>","DOI":"10.1002\/psp4.12943","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T07:55:44Z","timestamp":1676447744000},"page":"719-723","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus"],"prefix":"10.1002","volume":"12","author":[{"given":"Kefeng","family":"Sun","sequence":"first","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siobhan","family":"Hayes","sequence":"additional","affiliation":[{"name":"ICON plc  Reading UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colm","family":"Farrell","sequence":"additional","affiliation":[{"name":"ICON plc  Reading UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivy H.","family":"Song","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-6367(22)00630-3"},{"key":"e_1_2_8_3_1","unstructured":"Centers for Disease Control and Prevention (CDC).Clinical Growth Charts. Accessed March 11 2022.https:\/\/www.cdc.gov\/growthcharts\/clinical_charts.htm"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy706"},{"issue":"10","key":"e_1_2_8_5_1","first-page":"690","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post\u2010transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery RK","year":"2021","journal-title":"Clin Infect Dis"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1334-1342.2003"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-3487"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000174"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.554"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.43.s.3.5.x"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12943","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/psp4.12943","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T17:18:09Z","timestamp":1692465489000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.12943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/psp4.12943"],"URL":"https:\/\/doi.org\/10.1002\/psp4.12943","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"assertion":[{"value":"2022-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}